Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence

BACKGROUND: The oncogene LSF (encoded by TFCP2) has been proposed as a novel therapeutic target for multiple cancers. LSF overexpression in patient tumors correlates with poor prognosis in particular for both hepatocellular carcinoma and colorectal cancer. The limited treatment outcomes for these di...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Willoughby, Jennifer L. S., George, Kelly, Roberto, Mark P., Chin, Hang Gyeong, Stoiber, Patrick, Shin, Hyunjin, Pedamallu, Chandra Sekhar, Schaus, Scott E., Fitzgerald, Kevin, Shah, Jagesh, Hansen, Ulla
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7296649/
https://ncbi.nlm.nih.gov/pubmed/32539694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07039-1
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg